Table 1

Baseline patient demographic and disease characteristics

CharacteristicImatinib resistant (n = 200)Imatinib intolerant (n = 88)Total (N = 288)
No.%No.%No.%
Age, y
    Median51.054.553.0
    Range18-8623-9118-91
Sex, male11658384315453
Hematologic analysis, 109/L
    White blood cell count
        Median6.75.96.5
        Range2.1-1512.1-160.72.1-151
    Platelet count
        Median261.5202.5237.5
        Range47-243648-225147-2436
Duration of disease, y
    Median4.02.83.6
    Range0.1-15.10.1-13.60.1-15.1
Treatment history
    No. of previous therapies*
        113166657419668
        2693523269232
    Previous IFN693523269232
    Previous stem cell transplantation632283
Features of imatinib treatment
    Duration of previous imatinib treatment, y
        Median2.61.52.2
        Range0.4-8.8< 0.1-8.3< 0.1-8.8
    Previous complete hematologic response with imatinib16482556321976
    Reason for stopping imatinib
        Adverse event (intolerance)1186988733
        Disease progression163921116462
        Regimen completed740083
        Other741173
        Missing22022
    1 or more Bcr-Abl mutations detected§57/83698/322565/11557
  • * Includes previous tyrosine kinase inhibitor therapies. Percentages may not total 100% because of rounding.

  • Patients simultaneously meeting the protocol definitions for imatinib resistance and imatinib intolerance are categorized as having imatinib resistance.

  • The reason for stopping imatinib was not reported.

  • § Total of 83 imatinib-resistant and 32 imatinib-intolerant patients assessed for mutation status at baseline.